Abstract
Underlying mechanisms for how bacterial infections contribute to active resolution of acute inflammation are unknown1,2,3,4. Here, we performed exudate leukocyte trafficking and mediator-metabololipidomics of murine peritoneal Escherichia coli infections with temporal identification of pro-inflammatory (prostaglandins and leukotrienes) and specialized pro-resolving mediators (SPMs). In self-resolving E. coli exudates (105 colony forming units, c.f.u.), the dominant SPMs identified were resolvin (Rv) D5 and protectin D1 (PD1), which at 12 h were at significantly greater levels than in exudates from higher titre E. coli (107 c.f.u.)-challenged mice. Germ-free mice had endogenous RvD1 and PD1 levels higher than in conventional mice. RvD1 and RvD5 (nanograms per mouse) each reduced bacterial titres in blood and exudates, E. coli-induced hypothermia and increased survival, demonstrating the first actions of RvD5. With human polymorphonuclear neutrophils and macrophages, RvD1, RvD5 and PD1 each directly enhanced phagocytosis of E. coli, and RvD5 counter-regulated a panel of pro-inflammatory genes, including NF-κB and TNF-α. RvD5 activated the RvD1 receptor, GPR32, to enhance phagocytosis. With self-limited E. coli infections, RvD1 and the antibiotic ciprofloxacin accelerated resolution, each shortening resolution intervals (Ri). Host-directed RvD1 actions enhanced ciprofloxacin’s therapeutic actions. In 107 c.f.u. E. coli infections, SPMs (RvD1, RvD5, PD1) together with ciprofloxacin also heightened host antimicrobial responses. In skin infections, SPMs enhanced vancomycin clearance of Staphylococcus aureus. These results demonstrate that specific SPMs are temporally and differentially regulated during infections and that they are anti-phlogistic, enhance containment and lower antibiotic requirements for bacterial clearance.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Enhanced silver nanoparticle-induced pulmonary inflammation in a metabolic syndrome mouse model and resolvin D1 treatment
Particle and Fibre Toxicology Open Access 06 August 2022
-
Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis
Scientific Reports Open Access 27 August 2021
-
Sepsis: deriving biological meaning and clinical applications from high-dimensional data
Intensive Care Medicine Experimental Open Access 07 May 2021
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Houck, J. C., ed. Chemical Messengers of the Inflammatory Process (Elsevier/North-Holland Biomedical Press, 1979)
Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev. Immunol. 11, 519–531 (2011)
Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell 140, 771–776 (2010)
Serhan, C. N. Resolution phases of inflammation: novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101–137 (2007)
Stables, M. J. & Gilroy, D. W. Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. 50, 35–51 (2011)
Henneke, P. & Golenbock, D. T. Phagocytosis, innate immunity, and host-pathogen specificity. J. Exp. Med. 199, 1–4 (2004)
Rossi, A. G. et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nature Med. 12, 1056–1064 (2006)
Dinarello, C. A. Anti-inflammatory agents: present and future. Cell 140, 935–950 (2010)
Navarro-Xavier, R. A. et al. A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. 184, 1516–1525 (2010)
Schif-Zuck, S. et al. Satiated-efferocytosis generates pro-resolving CD11blow macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41, 366–379 (2011)
De Caterina, R. n−3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364, 2439–2450 (2011)
Morris, T. et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089–2096 (2009)
Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R. & Serhan, C. N. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569–581 (2011)
Spite, M. et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287–1291 (2009)
Mead, P. S. et al. Food-related illness and death in the United States. Emerg. Infect. Dis. 5, 607–625 (1999)
Klingensmith, M. E. & Soybel, D. I. in The Physiological Basis of Modern Surgical Care ( Miller, T. A. & Rowlands, B. J. eds) 478–490 (Mosby Year Book, 1998)
Xu, Y. N., Zhang, Z., Ma, P. & Zhang, S. H. Adenovirus-delivered angiopoietin 1 accelerates the resolution of inflammation of acute endotoxic lung injury in mice. Anesth. Analg. 112, 1403–1410 (2011)
Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med. 196, 1025–1037 (2002)
Bäckhed, F., Manchester, J. K., Semenkovich, C. F. & Gordon, J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. USA 104, 979–984 (2007)
Krishnamoorthy, S. et al. Resolvin D1 binds human phagocytes with evidence for pro-resolving receptors. Proc. Natl Acad. Sci. USA 107, 1660–1665 (2010)
Grkovich, A., Johnson, C. A., Buczynski, M. W. & Dennis, E. A. Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. J. Biol. Chem. 281, 32978–32987 (2006)
Jin, S. L., Lan, L., Zoudilova, M. & Conti, M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J. Immunol. 175, 1523–1531 (2005)
Link, A., Selejan, S., Maack, C., Lenz, M. & Böhm, M. Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock. Crit. Care 12, R159 (2008)
Stables, M. J. et al. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood 116, 2950–2959 (2010)
World Health Organization. Antibiotics Resistance, Factsheet No. 194 http://www.who.int/mediacentre/factsheets/fs194/en/ (February 2011)
Seki, H. et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 184, 836–843 (2010)
El Kebir, D. et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am. J. Respir. Crit. Care Med. 180, 311–319 (2009)
Prescott, D. & McKay, D. M. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G487–G497 (2011)
Yang, R., Chiang, N., Oh, S. F. & Serhan, C. N. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr. Protoc. Immunol. 95, 14.26.11–14.26.26 (2011)
Winyard, P. G., Willoughby, D. A., eds. Inflammation Protocols (Humana, 2003)
Acknowledgements
The authors thank M. Small for assistance with manuscript preparation, J. Lederer for cytokine measurements, J. Dalli for discussions, and N. Petasis for preparation of deuterium-labelled RvD1. This work was supported in part by NIH grants P01GM095467 and R01GM38765 (C.N.S.).
Author information
Authors and Affiliations
Contributions
N.C., G.F. and S.F.O. contributed to experimental design, carried out experiments and data analyses. T.V. and S.F.O. performed metabololipidomics and lipid mediator analyses. F.B. carried out experiments with germ-free mice and contributed to manuscript composition. B.A.S. carried out dermatopathology. All authors contributed to manuscript presentation and figure preparation. N.C. and C.N.S. carried out overall experimental design and C.N.S. conceived of the overall research plan.
Corresponding author
Ethics declarations
Competing interests
C.N.S. is an inventor on patents (resolvins) assigned to BWH and licensed to Resolvyx Pharmaceuticals. C.N.S. is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company. C.N.S.’ interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.
Supplementary information
Supplementary Information
This file contains Supplementary Tables 1-3, Supplementary Figures 1-11 and an additional reference. (PDF 24452 kb)
Rights and permissions
About this article
Cite this article
Chiang, N., Fredman, G., Bäckhed, F. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524–528 (2012). https://doi.org/10.1038/nature11042
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature11042
This article is cited by
-
Enhanced silver nanoparticle-induced pulmonary inflammation in a metabolic syndrome mouse model and resolvin D1 treatment
Particle and Fibre Toxicology (2022)
-
Effect of resolvin D1 on experimental bacterial keratitis to prevent corneal scar
Graefe's Archive for Clinical and Experimental Ophthalmology (2022)
-
Sepsis: deriving biological meaning and clinical applications from high-dimensional data
Intensive Care Medicine Experimental (2021)
-
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Nature Reviews Drug Discovery (2021)
-
Activation of GPR37 in macrophages confers protection against infection-induced sepsis and pain-like behaviour in mice
Nature Communications (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.